Table 1 Baseline Characteristics of the 212 patients with chronic liver disease.

From: TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

 

Control (n = 80)

Chronic liver disease

Hepatitis (n = 140)

Cirrhosis(n = 72)

Average age, years (range)

41.86(20,70)

45.34(15,86)

48.94(19,74)a

Gender

Male (%)

53(66.25)

79(56.43)

55(76.39)

Female (%)

27(33.75)

61(43.57)

17(23.61)b

Serum ALT level (U/L),(Median, range)

20.70(15.33,25.88)

28.25(17.38,50.60)a

29.25(20.73,48.50)a

Serum AST leve (U/L),(Median, range)

19.90(16.98,22.68)

26.75(20.65,41.68)a

35.25(24.13,54.33)ab

APRI score (Median, range)

0.24(0.18,0.31)

0.49(0.34,0.77)a

1.41(0.64,2.62)ab

PLT(× 109/L) (Median, range)

232.00(197.75,281.50)

174.50(135.25,213.75)a

88.00(57.25,129.75)ab

HBsAg (> 0.4 IU/mL)

Negative (%)

80(100)

31(22.14)

7(9.72)

Positive (%)

0(0)

109(77.86)a

65(90.28)ab

FIB-4 Index (Median, range)

0.75(0.57,0.98)

1.46(0.93,2.22)a

4.04(1.89,7.86)ab

TET3 ng/mL

127.58(96.99,163.7)

268.10(133.97,900.56)a

1148.09(362.64,1451.11)ab

  1. aP < 0.05 versus control; bP < 0.05 versus hepatitis.
  2. Abbreviations:ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIB-4, fibrosis-4; APRI, AST to platelet ratio Index; PLT, platelet count; HBsAg, Hepatitis B surface antigen; TET3, Ten-eleven translocation protein 3.